Very plausible scenario, as we see how delays happen sometimes and trials don't move as fast as us anxious investors woud like! I still think the wild card here is the breakthrough therapy designation, and shooting straight from phase 1 to phase 3. I think that news will give us a DNDN type gap up with no looking back. Regardless, I know we have a great base of loyal and dedicated long term shareholders and we are riding it out whether its 9,12,18,24 months.
